Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - September 2012


Expertise in Neuropharmacology

Autumn News

Serotonin Club meeting

Adrian Newman-Tancredi PhD chaired a session at the Serotonin Club meeting in Montpellier, France on 16th July. The symposium was entitled "From ligand functional selectivity to brain region selectivity: differential pharmacological targeting of the serotonin system." For details of the symposium click here.

25th ECNP Congress, Vienna 

Adrian will be presenting at a symposium of the 25th European College of Neuropsychopharmacology (ECNP) in Vienna, Austria, on 15th October 2012. The symposium is entitled "New mechanisms and novel therapeutics: how recent discoveries are opening perspectives for targeting serotonin 5-HT1A receptor function." Adrian's lecture will focus on novel drugs exhibiting biased agonism. For details of the symposium click here.

Academic contacts

Adrian acted as external examiner for a PhD candidate at Descartes University, Paris, on 11th June 2012. The thesis work, carried out by Dr. Cédric Martin, in the laboratory of Prof. Raymond Mongeau, concerned the signal transduction mechanisms of serotonin 5-HT2C receptors.

For more information on Adrian's lectures and neuropharmacology expertise: Consulting services.




Serotonin Club













NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.  


NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi Ph.D., an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile



Scientific Communication

Poster presentation:


Adrian co-presented a poster at the Serotonin Club meeting with Andrew McCreary PhD, a researcher with extensive experience of neurobiology research.

Antipsychotic Agents: Biased agonism at Serotonin 5-HT1A receptors.

McCreary A, Newman-Tancredi A.
Serotonin Club, Montpellier (France),
July 2012.

To find out more about Adrian's scientific communication, see his Publications








Neurolixis update

Adrian Newman-Tancredi is co-founder and Chief Scientific Officer of Neurolixis Inc., a CNS drug discovery and development start-up.

Neurolixis is advancing its program of in-licensing clinical assets and synthesis of Novel Chemical Entities.

Neurolixis is currently aquiring financing from investors and grant-awarding institutions to support its drug discovery and early development projects. For further information or to make an investment, Contact.